A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

Inclusion Criteria:

• Male and female participants aged 18 to 55 years, inclusive, at the time of signingthe informed consent.

• Overtly healthy with no clinically relevant abnormalities based on the medicalhistory, physical examinations, clinical laboratory evaluations, and 12-lead ECGthat, in the opinion of the investigator, would affect participant safety.

• Body mass index (BMI) within the range of 18-32 kg/m2 (inclusive).

Exclusion Criteria:

• Inability to take oral medications or gastrointestinal abnormalities potentiallyimpacting absorption

• Clinically significant cardiovascular, hematological, renal, hepatic, pulmonary,endocrine, gastrointestinal, immunological, dermatological, neurological, orpsychiatric disease which could interfere with, or the treatment for which mightinterfere with, the conduct of the study or which would, in the opinion of theinvestigator, unacceptably increase the participant's risk by participating in thestudy

• Past or current history or evidence of alcohol abuse and/or dependence onrecreational drug use

• Donation of over 500 mL blood ≤ 3 months prior to start of participation

• Has known psychiatric disorders that would interfere with the cooperation with therequirements of the study

• Participant is under legal custodianship.